

Consolidated financials

CONSOLIDATED INCOME STATEMENTS FOR THE YEARS ENDED 31 DECEMBER

Thousands of €	2008	2007
Revenues	76,978	65,936
Cost of sales	-27,769	-30,166
Gross profit	49,209	35,770
Other income	825	1,545
R&D expenditure	-38,726	-30,633
General and administrative costs	-21,072	-19,444
Sales and marketing expenses	-2,327	-2,455
Restructuring and integration costs	-3,124	-6,623
Operating loss	-15,215	-21,840
Finance income	1,863	1,081
Finance costs	-5,126	-1,747
Loss before tax	-18,478	-22,506
Income tax	3,894	558
NET LOSS FOR THE YEAR	-14,584	-21,948
Weighted average number of ordinary shares in issue ('000)	21,189	20,680
Basic and diluted loss per share in €	-0.69	-1.06

CONSOLIDATED BALANCE SHEETS AT 31 DECEMBER
ASSETS

Thousands of €	2008	2007
NON-CURRENT ASSETS	58,975	67,981
Goodwill	33,751	33,952
Intangible assets	4,159	6,090
Property, plant and equipment	20,293	22,914
Deferred tax assets		352
Available for sale financial assets	772	1,049
Current income tax receivable		3,167
Other non-current assets		457
CURRENT ASSETS	59,849	80,743
Inventories	3,574	4,948
Trade and other receivables	18,208	16,935
Current income tax receivable	8,408	5,144
Cash and cash equivalents	27,316	49,295
Other current assets	2,343	4,421
• accrued income	1,012	2,741
• deferred charges	1,331	1,680
TOTAL ASSETS	118,824	148,724

Equity and liabilities

Thousands of €	2008	2007
TOTAL EQUITY	84,324	98,626
Share capital	110,855	110,855
Share premium account	48,268	48,268
Translation differences	-2,307	-1,535
Accumulated losses	-72,492	-58,962
TOTAL LIABILITIES	34,500	50,098
NON-CURRENT LIABILITIES	4,749	6,737
Pension liabilities	830	664
Provisions	850	2,498
Deferred tax liabilities	201	292
Finance lease liabilities	1,156	1,747
Other non-current liabilities	1,712	1,536
CURRENT LIABILITIES	29,751	43,361
Post employment benefit obligations		226
Provisions		933
Financial lease liabilities	530	2,621
Other financial liabilities	16	
Trade and other payables	13,425	13,293
Current income tax payable	56	56
Other current liabilities	15,724	26,232
• accrued charges	2,290	2,858
• deferred income	13,434	23,374
TOTAL LIABILITIES AND EQUITY	118,824	148,724

CONSOLIDATED CASH FLOW STATEMENTS FOR THE YEARS ENDED 31 DECEMBER

Thousands of €	2008	2007
CASH AND CASH EQUIVALENTS		
AT BEGINNING OF YEAR	49,295	51,519
Result from operations	-15,215	-21,866
Adjustments for:		
Depreciation of property, plant and equipment	6,014	6,643
Amortization of intangible fixed assets	1,352	1,711
Impairment loss on intangible assets	1,543	1,561
Inventories write off	367	
Loss on disposal of business	2,568	
Exchange loss(gain) on translation of net assets of subsidiary	961	-79
Share based compensation	1,161	1,098
Increase / Decrease provisions	-1,852	-1,507
Increase / Decrease pension liabilities (assets)	166	-15
Reclassification from cash and cash equivalents to available for sale financial assets.	-2,000	
Operating cash flows before movements in working capital	-4,935	-12,454
(Increase)/Decrease in inventories	502	-1,449
(Increase)/Decrease in receivables	1,352	-3,131
Increase/(Decrease) in payables	-9,588	14,094
Increase/(Decrease) in provisions	-844	
Cash used in operations	-13,513	-2,940
Interest paid and other financial costs	-709	-1,746
Taxes	4,013	5,057
NET CASH FLOWS USED IN OPERATING ACTIVITIES	-10,209	371
Purchase of property, plant and equipment	-5,702	-6,045
Purchase of and expenditure in intangible fixed assets	-1,512	-1,037
Proceeds from disposal of intangible assets	16	
Proceeds from disposal of property, plant and equipment	198	1,117
Acquisitions, disposals of subsidiaries, associates or joint ventures, net of cash acquired	-857	
NET CASH USED IN INVESTING ACTIVITIES	-7,857	-5,965

Thousands of €	2008	2007
Repayment of obligations under finance leases and other debts	-5,079	-2,506
Proceeds of Capital and Share premium increases, net of issue costs		4,829
Proceeds from share issues		
Interest received and other financial income	1,163	1,081
NET CASH FROM FINANCING ACTIVITIES	-3,916	3,404
INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	-21,982	-2,190
Effect of exchange rates on cash and cash equivalents	3	-34
CASH AND CASH EQUIVALENTS AT END OF YEAR	27,316	49,295

SEGMENT REPORTING

2008

Revenue				
Thousands of €	Drug Discovery	BioFocus DPI	Eliminations	Total
External sales	31,521	45,457		76,978
Inter-segment sales	223	10,914	-11,137	
Segment revenue	31,744	56,371	-11,137	76,978

Inter-segment sales are charged at prevailing market rates

RESULT				
Thousands of €	Drug Discovery	BioFocus DPI	Eliminations	Total
Segment result	-10,665	3,381		-7,284
Recurring result	-10,665	3,381		-7,284
Non-recurring result		-2,568		-2,568
Unallocated expenses				
• general and administrative costs				-4,809
• integration costs				-554
Operating loss				-15,215
Net finance costs	-114	-3,149		-3,263
Loss before taxation				-18,478
Income tax credit	4,101	-207		3,894
Net loss for the year				-14,584